ImmunityBio announced a commercial partnership with Biopharma and Cigalah Healthcare to launch its IL‑15 superagonist ANKTIVA in Saudi Arabia and, over time, across the Middle East and North Africa (MENA). The partnership follows the company’s recent regulatory milestones: the Saudi Food and Drug Authority approved ANKTIVA for BCG‑unresponsive non‑muscle invasive bladder cancer and for metastatic non‑small cell lung cancer in January 2026, and the European Commission granted conditional marketing authorization in February 2026.
The agreement gives Biopharma and Cigalah responsibility for commercialization and distribution, allowing ANKTIVA to reach patients in Saudi Arabia within 60 days of the announcement. The move is a key element of ImmunityBio’s global expansion strategy, positioning the company to tap a sizable patient population in the MENA region—estimated to represent a significant share of the regional bladder and lung cancer market—and to accelerate revenue growth beyond its established U.S. and European operations.
Financially, ImmunityBio projected fiscal‑year 2025 revenue of $113 million, a 700% increase over the prior year, underscoring strong commercial traction. The company remains unprofitable, with negative EBITDA and declining earnings, but maintains robust liquidity. The partnership is expected to contribute materially to the company’s top‑line growth in the coming years, aligning with its broader strategy to scale ANKTIVA’s market presence worldwide.
Richard Adcock, President and CEO of ImmunityBio, said the partnership “leverages Biopharma and Cigalah’s world‑class commercial infrastructure and proven track record” to ensure patients in Saudi Arabia and the MENA region have timely access to ANKTIVA. Tamer Eissa, General Manager of Biopharma, added that the goal is to “ensure physicians and patients have access to advanced therapies like ANKTIVA.”
The partnership was a key driver behind the recent surge in the company’s stock, following the European Commission approval. Analysts noted the company’s expanding regulatory footprint and the strategic importance of the MENA market, highlighting the partnership as a significant step in ImmunityBio’s growth trajectory.
Overall, the announcement marks a material expansion of ANKTIVA’s commercial reach into a high‑potential market, reinforcing ImmunityBio’s position as a leader in IL‑15 oncology therapeutics and setting the stage for accelerated revenue growth in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.